Zacks Investment Research upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a hold rating in a research report released on Friday morning.
According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
Several other equities analysts have also recently commented on ATRA. BidaskClub cut shares of Atara Biotherapeutics from a hold rating to a sell rating in a research note on Friday, August 10th. Cowen reissued a buy rating on shares of Atara Biotherapeutics in a research note on Friday, November 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Atara Biotherapeutics has an average rating of Buy and an average price target of $47.80.
Shares of ATRA stock traded up $0.53 during trading hours on Friday, reaching $40.20. The stock had a trading volume of 424,951 shares, compared to its average volume of 529,968. The stock has a market cap of $1.81 billion, a PE ratio of -10.05 and a beta of 2.61. Atara Biotherapeutics has a twelve month low of $13.85 and a twelve month high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by ($0.16). On average, analysts expect that Atara Biotherapeutics will post -4.82 earnings per share for the current fiscal year.
In other news, insider Joe Newell sold 1,500 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $41.28, for a total transaction of $61,920.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 3,900 shares of the firm’s stock in a transaction dated Monday, October 22nd. The shares were sold at an average price of $33.78, for a total transaction of $131,742.00. Following the transaction, the chief executive officer now owns 733,285 shares of the company’s stock, valued at approximately $24,770,367.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 89,349 shares of company stock worth $3,448,853. 10.60% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the company. State of Wisconsin Investment Board boosted its position in shares of Atara Biotherapeutics by 53.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 41,400 shares of the biotechnology company’s stock valued at $1,521,000 after purchasing an additional 14,500 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Atara Biotherapeutics by 16.9% during the 2nd quarter. Rhumbline Advisers now owns 39,238 shares of the biotechnology company’s stock valued at $1,442,000 after purchasing an additional 5,673 shares in the last quarter. United Services Automobile Association boosted its position in shares of Atara Biotherapeutics by 28.4% during the 2nd quarter. United Services Automobile Association now owns 8,132 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 1,797 shares in the last quarter. Highland Private Wealth Management bought a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at about $202,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Atara Biotherapeutics by 35.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock valued at $49,741,000 after purchasing an additional 315,921 shares in the last quarter.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: Dollar Cost Averaging
Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.